Author Index to Volume 5

Al-Jabally M. See Fido AA
Aman MG. Efficacy of Psychotropic
Drugs for Reducing Self-Injurious
Behavior in the Developmental
Disabilities, 171

Arnold LE. Clinical Pharmacological Issues in Treating Psychiatric Disorders of Patients with Mental Retardation, 189

Bannerman DJ. See Harchik AE
Beasley CM Jr. Fluoxetine Compared
with Imipramine in the Treatment
of Inpatient Depression: A
Multicenter Trial, 199
Beasley CM Jr. See Tollefson GD
Black DW. See Lauer J
Bornstein RA. See Olson SC

Campbell DA. See Varney NR Cook BL. See Varney NR Csernansky JG. Abnormalities of Serotonin Metabolism and Nonpsychotic Psychiatric Disorders, 275

Borthwick-Duffy SA. See Rojahn J

Dewan MJ. See Huszonek JJ

Cutler R. See Fishbain DA

Faries DE. See Tollefson GD
Fava M. See Guaraldi GP
Fawcett J. See Tollefson GD
Fido AA. Presence of Psychiatric
Morbidity in Prison Population in
Kuwait, 107
Fishbain DA. Opiate Detoxification

Protocols: A Clinical Manual, 53

Garvey MJ. See Varney NR
Gietzen DW. See Magliozzi JR
Gold AS. See Magliozzi JR
Guaraldi GP. An Open Trial of
Methyltetrahydrofolate in Elderly
Depressed Patients, 101
Guze SB. Genetics of Briquet's Syndrome
and Somatization Disorder, 225

Harchik AE. Choice and Control: New Opportunities for People with Developmental Disabilities, 151 Hardoby WJ. See Huszonek JJ Hayes SG. Barbiturate Anticonvulsants in Refractory Affective Disorders, 35 Holman SL. See Beasley CM Jr

Annals of Clinical Psychiatry 5:289, 1993 ©1993 Elsevier Science Publishing Co., Inc 655 Avenue of the Americas, New York, NY 10010

Huszonek JJ. Antidepressant Side Effects

and Physician Prescribing Patterns,

Ispahani A. See Huszonek JJ

Jacobson JW. See Rojahn J

Kathol RG. See Long TD Keen P. See Lauer J Koponen H. See Leinonen E Koss M. See Huszonek JJ

la Greca P. See Guaraldi GP Langbehn DR. Clinical Correlates of Self-Mutilation Among Psychiatric Inpatients, 45

Lauer J. Multiple Personality Disorder and Borderline Personality Disorder: Distinct Entities or Variations on a Common Theme?, 129

Leinonen E. Delerium During Fluoxetine Treatment: A Case Report, 255

Lepola U. See Leinonen E Long TD. Critical Review of Data Supporting Affective Disorder Caused by Nonpsychotropic Medication, 259

Lynn P. See Sullivan M

Maddock RJ. See Magliozzi JR Magliozzi JR. Relationships Between Thyroid Indices and Symptoms of Anxiety in Depressed Outpatients, 111

Masand P. Bupropion and Secondary Mania: Is There A Relationship?, 271

Mazzi F. See Guaraldi GP
McCoy L. Clinical Correlates of
Valproate Augmentation in
Refractory Bipolar Disorder, 29

Merikangas JR. Introduction: Special Treatment Section on Mental Retardation, 149

Minnema AM. See Reddig S Mirchandani IC. Management of Mania in the Elderly: An Update, 67

Nasrallah HA. See McCoy L
Nasrallah HA. See Olson SC
Nelson EC. A Calendar Savant with
Autism and Tourette Syndrome:
Response to Treatment and
Thoughts on the Interrelationships
of These Conditions, 135

Olson SC. Are Controls in Schizophrenia Research "Normal"?, 1

Pariser SF. Women and Mood Disorders:

Menarche to Menopause, 249
Pfohl B. See Langbehn DR
Piper A Jr. Tricyclic Antidepressants
Versus Electroconvulsive Therapy:
A Review of the Evidence for
Efficacy in Depression, 13
Potvin JH. See Beasley CM Jr
Potvin JH. See Tollefson GD
Pribor EF. See Nelson EC

Rampey AH Jr. See Tollefson GD Rasmussen SA. Genetic Studies of Obsessive-Compulsive Disorder, 241

Reddig S. Neuroleptic Malignant Syndrome and Clozapine, 25 Reus VI. Rational Polypharmacy in Treatment of Mood Disorders, 91

Roberts RJ. See Varney NR
Rojahn J. The Association Between
Psychiatric Diagnoses and Severe
Behavior Problems in Mental
Retardation, 163

Rojahn J. See Merikangas JR Rosomoff HL. See Fishbain DA Roy-Byrne P. See Sullivan M

Sayler ME. See Tollefson GD
Schwarzkopf SB. See McCoy L
Schwarzkopf SB. See Olson SC
Sheldon JB. See Harchik AE
Sheline YI. See Csernansky JG
Sherman JA. See Harchik AE
Steele Rosomoff R. See Fishbain DA
Stern TA. See Masand P
Sullivan M. Phenobarbital Versus
Clonazepam for Sedative-Hypnotic
Taper in Chronic Pain Patients: A
Pilot Study, 123

Tandon R. See Reddig S
Tollefson GD. Evaluation of Suicidality
During Pharmacologic Treatment
of Mood and Nonmood Disorders,
209

Toshima M. See Sullivan M

Varney NR. Identification of Treatment-Resistant Depressives Who Respond Favorably to Carbamazepine, 117 Votolato NA. See McCoy L

Winokur G. See Tollefson GD Wolkowitz OM. Rational Polypharmacy in Schizophrenia, 79 Woodman CL. The Genetics of Panic Disorder and Generalized Anxiety Disorder, 231

Young RC. See Mirchandani IC



Subject Index to Volume 5

AACP 1993 Meeting Paper Abstracts Acetazolamide in Primary Psychiatric Disorders, 286

Addiction Treatment Outcome in Depressed Patients, 286

Blood Pressure and Heart Rate Response of Panic Disorder Patients Receiving Imipramine in a Dose-Response Treatment Paradigm, 284

Comorbidity in Dysphoric Compared with Pure Mania, 285

Comorbidity in First Compared with Multiple Episode Mania, 285

Is a Sedating Antidepressant Better than a Non-Sedating Agent in Agitated Depression, 284 Neurogenic or Psychogenic:

Depression and Cancer, A Consecutive Case Series, 283 O.C.D., Spect, and Clinical Outcome,

A Placebo-Controlled Trial of Sertindole in Schizophrenia, 283

Predictors of Response to Clozapine in Chronic Schizophrenia, 283

A 16 to 45 Year Follow-up of 71 Males with Antisocial Personality Disorder, 286

Acetazolamide, 286
Affective disorders, 35
Aggressive behavior, 163
Agitation, 284
Agoraphobia, 111
Alcoholism, 107
Anticonvulsants, 35
Antidepressants, 7, 13, 79, 91, 117, 284
Antisocial personality disorder, 286
Anxiety, 111, 123
Autism, 135
Avoidance, 111

Barbiturates, 35
Beck Anxiety scores, 123
Beck Depression scale, 117
Behavior problems, 163, 171
Benzodiazepines, 79, 123
Beta blockers, 171
Bipolar disorder, 29
Blood pressure, 284
Book Reviews
The Brain Has a Mind of Its

The Brain Has a Mind of Its Own by Restak R, 143 Evaluation of the Psychiatric Patient, a Primer by Halleck SL, 146 Eyewitness: A Personal Account of the

Annals of Clinical Psychiatry 5:291–292, 1993 ©1993 Elsevier Science Publishing Co., Inc 655 Avenue of the Americas, New York, NY 10010 Unraveling of the Soviet Union by Pozner V, 142

I'm Dysfunctional, You're Dysfunctional by Kaminer W, 141

The Medical Interview: The Three-Function Approach by Cohen-Cole SA, 146

Menninger—The Family and the Clinic by Friedman LJ, 147

Pain Control After Surgery. A Patient's Guide by the US Department of Health and Human Services. Public Health Services, 144

Psychiatric Interviewing, a Primer, 2nd Edition by Leon RL, 146

Psychiatric Malpractice: Cases and Comments for Clinicians by Simon RI and Sadoff RL, 145

Psychiatric Services to Adult Mentally Retarded and Developmentally Disabled Persons—Report 30 by the American Psychiatric Association, 144

Psychiatry and Law for Clinicians by Simon RI, 146

A Question of Character: A Life of John F. Kennedy by Reeves TC, 142

Utilization Management—A Handbook for Psychiatrists by the Committee on Managed Care of the American Psychiatric Association, 143

Where the Buck Stops: The Personal and Private Writings of Harry S. Truman, Truman M (ed.), 142

Why Psychiatry is a Branch of Medicine by Guze SB, 141

Borderline personality disorder, 129 Brain, 101, 189

Calendar savant, 135
Cancer, 283
Carbamazepine, 79, 117
Caregivers, 189
Choice making, 151
Chronic pain patients, 123
Clomipramine, 135
Clonazepam, 123
Clonidine, 79
Clozapine, 25
Cognitive performance, 117
Comorbidity, 189, 285
Constipation, 199
Controls, research, 1
Crime, 107

Depression, 13, 91 addiction and, 286 agitated, 284 cancer and, 283 in elderly, 101 inpatient, 199 schizophrenia and, 79
thyroid indices and, 111
treatment-resistant, 117
Detoxification protocols, 53
Developmental disabilities, 151, 171, 189
Dichotic word listening performance,
117
Distortion, of symptoms, 189
Dose-response treatment paradigm, 284

Drug abuse problems, 107
Drug response, in mental retardation,
189

Drug smuggling, 107 Dry mouth, 199 Dysphoria, 285

Ecobehavioral considerations, 189
Elderly
depression in, 101
mania in, 67
Electroconvulsive therapy, 13, 79
End-of-curve-phenomena, 189
Expected drug benefits, 189

Financial embezzlement, 107 Fluoxetine, 199

Generalized anxiety disorder, 107

Hamilton depression scale, 117 Headache, 199 Heart rate, 284

Imipramine, 199, 284 Infantile autism, 135 Inpatients, 45, 199

Kuwaiti prison, 107

L-dopa, 79 Liquid pain cocktail, 123 Liquor smuggling, 107 Lithium, 79, 171

Major depressive disorder, 199
Mania, 67, 91
multiple episode, 285
pure, 285
Masking, of symptoms, 189
Mental retardation, 149, 151, 163, 171, 189
Methyl groups, 101
Methyltetrahydrofolate, 101
Minnesota Multiphasic Personality
Inventory, 123
Mood disorders, 91
Multiple episode mania, 285
Multiple personality disorder, 129

Neuroleptic malignant syndrome, 25 Neuroleptics, 79, 171 Neuronal substrate, 189 Neuropsychological variables, 117

Obsessive-compulsive disorder, 135, 285 Opiate antagonists, 171 Opiates, 53 Organic mood syndrome, 117 Outpatients, 111

Pain, chronic, 123 Panic disorder, 111, 284 Partial seizure symptoms, 117 Personal control, 151 Personality disorder, 107 Pharmacotherapy, 189 Phenobarbital, 123 Prescribing patterns, physician, 7 Prison population, 107 Probation service, lack of, 107 Property destruction, 163 Propranolol, 79 Psychiatric diagnosis, 123, 163 Psychiatric morbidity, 107 Psychopharmacology, 91 Psychosis, 107 Psychotropic drugs, 171 Pure mania, 285

Qualitative-brain differences, 189

Ratcheting, 189
Rational polypharmacy, 79, 91
Rebound anxiety, 123
Recidivism, 107
Recurrent anxiety, 123
Reserpine, 79
Responsiveness, to lower dosage, 189
Ripples, 189
Risk-benefit ratio, 91

s-adenosyl-l-methionine (SAMe), 101
Savant syndrome, 135
Schizophrenia
clozapine and, 283
normal" controls in research on, 1
rational polypharmacy in, 79
sertindole and, 283
Sedation, 284
Sedative-hypnotic taper, 123
Self-injurious behavior, 163, 171
Self-mutilation, 45
Serotonin reuptake blockers, 171

Sertindole, 283
Side effects, drug
antidepressant, 7

fluoxetine and imipramine, 199 in mental retardation, 189 Sociocultural factors, 107 Somnolence, 199 SPECT imaging, 285 State anxiety, 111 Statistical quirks, 189 Stereotypies, 163, 171

Target symptoms, 189
Therapeutic community, prison-based, 107
Thioridazine, 171
Thyroid stimulating hormone (TSH), 111
Thyroxine, 111
Titration, slow, 189
Tolerance, drug, 91
Tourette syndrome, 135
Toxicity, drug, 189
Trait anxiety, 111
Treatment resistance, 91, 117
Tricyclic antidepressants, 13, 117

Valproate, 29 Valproic acid, 79

Withdrawal, 123